Concord Biotech Limited will host an earnings conference call on Monday, August 03, 2026, at 3:30 PM IST to discuss its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The event provides investors with direct access to management for insights into the company's operational performance and strategic outlook following the declaration of its Q1FY27 results.

The disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Para A of Schedule III. Paritosh Trivedi, Company Secretary and Compliance Officer, signed the submission to the National Stock Exchange of India Limited and BSE Limited on July 28, 2026. The filing confirms that the earnings call invite has been enclosed with the exchange submissions for record-keeping purposes.

Management Participants

Senior leadership from Concord Biotech will participate in the discussion to address investor queries regarding the quarterly performance. The confirmed participants are as follows:

Conference Call Details

The conference call is organized in association with IIFL. Participants can join via pre-registration through the provided Diamond Pass link or by dialing the designated numbers. The schedule accommodates global investors with simultaneous time zone conversions listed for Hong Kong, Singapore, the UK, and the USA.

For further information or registration assistance, investors may contact Naman Bagrecha, Rahul Jeewani, Aman Goyal, or Vighnesh Indure at IIFL Capital Markets using the provided contact details.

Concord Biotech Limited has fixed Friday, July 24, 2026, as the record date to determine shareholder eligibility for a final dividend of ₹7.55 per equity share for the financial year ended March 31, 2026. The dividend, equivalent to 755% on the face value of ₹1 each, is subject to approval by shareholders at the 41st Annual General Meeting. If approved, the payment will be made by August 30, 2026, subject to deduction of tax at source.

The company will hold its AGM on Friday, July 31, 2026, at 12:00 Noon through Video Conferencing and Other Audio-Visual Means. Pursuant to Regulation 42 of the SEBI Listing Regulations, the Register of Members and Share Transfer Books will be closed from Saturday, July 25, 2026, to Friday, July 31, 2026 (both days inclusive). The meeting agenda includes the adoption of audited financial statements for FY26 and the re-appointment of Mr. Ankur Vaid as Director.

Shareholders will also vote on the appointment of Mrs. Ekta Gupta as an Independent Director for a term of five years effective from June 01, 2026. Additionally, the company seeks approval to enhance the limit for loans, guarantees, and securities to subsidiaries, associates, and joint ventures to ₹500 Crores from the existing limit of ₹115 Crores. The ratification of remuneration for Cost Auditors, M/s. Dalwadi & Associates, at ₹3,70,000 plus applicable Goods and Services Tax for FY27 is also on the agenda.

Key Meeting Details

The Notice of AGM along with the Annual Report 2025-26 will be sent electronically to members, with physical copies available upon request. These documents will also be accessible on the company's website and the websites of BSE Limited and National Stock Exchange of India Limited.